Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) is a biotechnology leader pioneering RNA-targeted therapies through its antisense technology platform. This news hub provides investors and industry professionals with comprehensive updates on the company's clinical developments, strategic partnerships, and regulatory milestones.
Access real-time updates on Ionis' innovative research in neurology, cardiology, and rare diseases, including progress on therapies like Qalsody and Wainua. The page aggregates essential information including earnings reports, collaboration announcements with partners such as Biogen and AstraZeneca, and clinical trial outcomes.
Our curated collection serves as your primary source for tracking Ionis' advancements in antisense oligonucleotide development and commercialization strategies. Bookmark this page for streamlined access to verified updates about licensing agreements, patent developments, and therapeutic pipeline expansions.
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has appointed Michael Yang, an experienced biopharmaceutical executive, to its Board of Directors, expanding the total number of members to 10. Mr. Yang has over 20 years of leadership experience in biotech, pharmaceutical, and medical device companies, with significant achievements in launching new platforms, expanding global revenues, and diversifying product lines. His most recent role was as President, CEO, and Board member of ViaCyte, which was acquired by Vertex in 2022. Ionis' CEO, Brett P. Monia, and Board Chairman, Joseph Loscalzo, M.D., Ph.D., expressed excitement about Michael's appointment, highlighting his deep biopharmaceutical leadership experience and strong patient focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
-
Rhea-AI Summary
IONIS: Part 1 of HALOS trial for ION582 in Angelman syndrome completes enrollment with positive preliminary findings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IONIS Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of donidalorsen, showing a sustained 96% reduction in hereditary angioedema attacks over two years. Patients reported improved quality of life. Phase 3 results are expected in H1 2024. The drug received orphan drug designation in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. will participate in fireside chats at several investor conferences in November and December 2023. The conferences include Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference, Stifel 2023 Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference 2023, and BMO 2023 Growth & ESG Conference. The presentations will be webcasted live on the Ionis website and replays will be available within 48 hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.91%
Tags
-
Rhea-AI Summary
Ionis Pharmaceuticals reported positive Phase 3 data for Olezarsen, showing significant triglyceride lowering and reductions in acute pancreatitis attacks. Eplontersen is on track for regulatory approval in the EU and Canada, with potential approval in the US in December 2023. Ionis expects to achieve its 2023 financial guidance. Revenue for Q3 2023 was $144 million, a 10% decrease compared to the same period last year. Operating expenses increased due to investments in eplontersen, olezarsen, and donidalorsen. Ionis has $2.2 billion in cash and short-term investments as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
-
Rhea-AI Summary
Ionis Pharmaceuticals to host webcast to discuss Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
Rhea-AI Summary
Ionis Pharmaceuticals plans to bring new neurology medicines to its clinical pipeline by the end of 2024, positioning the company for significant revenue growth and positive cash flow. Last week, Ionis announced positive Phase 3 results for olezarsen in familial chylomicronemia syndrome, paving the way for independent commercial launches. Ionis also highlighted progress in its commercial and medical affairs organizations and the advancement of its neurology pipeline. The company has a strong financial foundation with $2B in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
Rhea-AI Summary
Publication of NEURO-TTRansform study shows eplontersen halted disease progression and improved quality of life in patients with ATTRv-PN. Eplontersen achieved an 82% reduction in TTR serum concentration compared to placebo group. It also demonstrated significant benefits on neuropathy impairment and quality of life. FDA action date in December. Ionis and AstraZeneca seeking regulatory approval globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
-
Rhea-AI Summary
Roche gains exclusive worldwide rights to develop, manufacture and commercialize investigational medicines for Alzheimer's disease and Huntington's disease discovered by Ionis. Ionis to receive $60 million upfront payment. Collaboration aims to accelerate the discovery and development of novel therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
Rhea-AI Summary
Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in FCS patients, with a statistically significant reduction in triglyceride levels and a 100% reduction in acute pancreatitis events. Plans to file a New Drug Application with the FDA. Favorable safety profile. Potential to become new standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.49%
Tags
Ionis Pharmaceuticals
Nasdaq:IONS
IONS Rankings
IONS Stock Data
4.56B
154.80M
0.83%
105.1%
8.09%
Biotechnology
Pharmaceutical Preparations
United States
CARLSBAD